Main

Inclusion Criteria:

- External condylomas, 1-15 lesions, non-confluent and individually isolated

- Lesions must not be internal; their visualization must be complete and easily
documented by digital pictures.

- Lesions to be treated should have appeared between 1-6 months before screening, and
should not have received any treatment since appearance.

- Non smoker or light smoker (< 10 cigarettes/day).

- Certified as healthy by a comprehensive clinical assessment.

- Having given a written informed consent prior to selection.

- For female patients: negative pregnancy test; postmenopausal woman with amenorrhea
for at least 2 years, or female of childbearing potential using one acceptable birth
control method until the end of the study.

- Ability to comply with protocol requirements.

- In agreement with the local law for biomedical experimentation.

Main Exclusion Criteria:

- Patients with VIN or PIN (ie,bowenoid papulosis), or genital disease requiring
treatment (ie, lichen sclerosus, lichen planus, lichen simplex chronicus, dermatitis,
psoriasis, bullous diseases, systemic diseases with genital manifestations).

- Patients with fibroepithelial polyps or scaly non-viral papillomas, seborrheic
keratosis, follicular papules, syringoma or circumscribed lymphangiomas.

- Patients who received any condyloma treatment during 12 months before screening.

- Patients whose skin condition or coloration would interfere with the observation and
the follow-up of the lesions during the study.

- Patients with any clinically significant abnormality following review of pre-study
laboratory tests, vital signs, full physical examination and ECG

- Patients with presence or history of any allergy or unusual reactions to drugs or
anesthetics.

- Patients in the exclusion period of a previous study or participated in a study
during the last 3 months.

- Patients who cannot be contacted in case of emergency.

- Patients with positive HBs or HBc antigen or anti HCV antibody, or positive results
for HIV 1 or 2 tests.